P3, N=116, Completed, Heron Therapeutics | Phase classification: P3b --> P3

P4, N=150, Not yet recruiting, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Intermediate-region APC mutations (e.g., codons 607 and 1062) predict an indolent course in mesenteric DTs. Comprehensive APC genotyping at diagnosis enables risk-adapted management, permitting safe use of conservative strategies (active surveillance/low-intensity therapy) and helps avoid unnecessary aggressive interventions. This underscores the critical role of molecular profiling in personalizing DT care.

P4, N=86, Enrolling by invitation, Washington University School of Medicine | Not yet recruiting --> Enrolling by invitation

Both probes integrate a celecoxib ligand for COX-2 targeting with a naphthalimide fluorophore...MM/PBSA calculations revealed favorable binding enthalpies for both S1 (-80.05 ± 7.19 kcal/mol) and S2 (-83.76 ± 3.88 kcal/mol) with COX-2, confirming stable and specific complex formation. This integrated experimental and computational strategy yields highly sensitive and selective probes, positioning S1 and S2 as promising tools for studying cancer-related biomarkers at the cellular level.

P4, N=120, Not yet recruiting, University of Miami | Initiation date: Jan 2026 --> Jun 2026

P2, N=40, Withdrawn, Sydney Local Health District | Not yet recruiting --> Withdrawn

In conclusion, this study shows that the combination of TQ with IR, Clx, or both exerts significant effects on SW620 colon cancer cells, such that by enhancing DNA damage, TQ may induce G2/M cell cycle arrest and apoptosis, while reducing inflammatory responses, oxidative stress, and G0/G1 cell cycle arrest. These in vitro findings indicate that TQ may enhance the chemotherapeutic effects of IR and act as a potential adjuvant therapy; however, further in vivo studies are required to verify its suggested effects.

P=N/A, N=50, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University

P=N/A, N=600, Not yet recruiting, Beijing Jishuitan Hospital, Capital Medical University; Beijing Jishuitan Hospital, Capital Medical University

P=N/A, N=450, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hainan Huiyuantang Pharmaceutical Co., Ltd.

P=N/A, N=60, Completed, Affiliated Hospital of Jining Medical University; Affiliated Hospital of Jining Medical University